Medication info
Rosacrodi Tablet

Rosacrodi Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Geonil Biopharm Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 202000328 · Approved 2020.01.21 · Insurance code 073000650

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. In general, the maximum blood pressure-lowering effect is achieved approximately 3 weeks after treatment is started. This medicine may be administered with other antihypertensive medicines and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually adjusted doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even though their blood pressure is controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously, and if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Administration is not recommended for patients with more severe renal impairment, as loop diuretics are preferable to thiazide-type medicines in these patients. ○ Patients with hepatic impairment Administration is not recommended for these patients because the initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment, 25 mg, cannot be given using this medicine.
Child dose
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Geonil Biopharm Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for hypertension that is not adequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. In general, the maximum blood pressure-lowering effect is achieved approximately 3 weeks after treatment is started. This medicine may be administered with other antihypertensive medicines and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually adjusted doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even though their blood pressure is controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously, and if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Administration is not recommended for patients with more severe renal impairment, as loop diuretics are preferable to thiazide-type medicines in these patients. ○ Patients with hepatic impairment Administration is not recommended for these patients because the initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment, 25 mg, cannot be given using this medicine.

Child dose

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus and newborn, especially during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Do not use this medication if you have allergic reactions to it or have certain kidney dysfunctions, liver dysfunctions, or electrolyte imbalances. Patients with hypotension, problems with renal blood vessels, the elderly, or those with a history of diabetes or gout should use this medication with caution. During use, be cautious of symptoms like dizziness or drowsiness, especially when starting the medication or changing doses, as blood pressure can drop too low. This medication can increase potassium levels, so do not take potassium supplements or salt substitutes containing potassium without a doctor's instructions. Due to the hydrochlorothiazide component, side effects such as electrolyte imbalance, increased blood sugar, hyperuricemia, skin rashes, acute angle-closure glaucoma may occur, necessitating regular blood tests and symptom monitoring. While taking this medication, reduce exposure to sunlight or UV rays, and consult a doctor immediately if any skin abnormalities occur. This medication may interact with other blood pressure medications, diuretics, hypoglycemic agents, anti-inflammatory drugs, etc., so inform your physician of any other medications you are taking. This medication should be used cautiously during pregnancy or breastfeeding, and if breastfeeding, you may need to stop nursing or discuss with your doctor since this medication can be transmitted through breast milk. Safety in children and adolescents has not been established, so this medication should not be administered to children. In case of overdose, hypotension and irregular heartbeats may occur, so the prescribed dosage should be strictly followed, and if unusual symptoms appear, seek medical help immediately. Keep this medication out of reach of children, and store it in its original container; transferring to another container may lead to misuse or quality degradation.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 128 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • skin exfoliation
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neuroexcitation
  • panic disorder
  • dysesthesia
  • peripheral neuropathy
  • sleep disturbance
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • dysgeusia
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequent urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasm
  • restlessness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • skin and mucosal syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythematous skin syndrome
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a tightly sealed container that blocks light. The storage temperature should be kept at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.